Skip to content

Phoenix Certificate

Already thought lost, but possibly soon in new splendour:
The new Phoenix convertible bond certificate in cooperation with Acatis and Genève Invest

The asset management companies Acatis and Genève Invest are pleased with the investment opportunity currently offered by the convertible bond market. The turnaround in times of increased interest rates and fallen share prices offers an ideal prerequisite for convertible bonds. On the one hand, this type of security offers the security of a bond, through a fixed redemption date at nominal value and an interest coupon. On the other hand, a recovery of the stock markets can lead to a disproportionate increase in the price of the convertible bond, through which one profits thanks to the conversion option into shares.
Logo Genève Invest
Disclaimer: This product is aimed exclusively at professional and institutional investors. Private clients are not eligible for this product. This document is promotional material and does not constitute advice or an investment recommendation. Past performance is not a reliable indicator of current and future performance and losses are possible. The occurrence of forecasts cannot be guaranteed.

Seizing opportunities in times of war and inflation

Together with our business partner Acatis, we launched a convertible bond product (“Phoenix”) in December, which was issued as a certificate at UBS.

The background was the massive distortions on the convertible bond market. Sharp price losses of the underlying shares reduced the probability of conversion.

What remains is an interest component that in many cases exceeds 10% p.a.

Why are convertible bonds attractive now?

An economic slowdown deep into 2023 is already priced into the current prices of convertible bonds. The asymmetric performance makes convertible bonds particularly interesting in an uncertain market environment. Long-term return expectations for convertible bonds have risen significantly for three reasons:
The Phoenix convertible bond certificate is therefore an attractive investment opportunity and is suitable both as an addition to a portfolio and as a stand-alone investment solution.

Request a free analysis of your investment portfolio now.

Discover the investment strategies we have devised for you.

We call you without obligation.

Fill out the form and we will contact you to give you more information.
Fields marked with * are required, other information can help us  improve our proposal.
Genève Invest accepts mandates starting at € 100.000


The information and content in these web pages represent neither a public offer nor a request to submit an offer for the purchase of securities, fund shares or financial instruments. An investment decision regarding the products presented here should be made only on the basis of the pertinent sales documents (sales prospectus, essential investor information, half-year or annual report) and under no circumstances on the basis of these web pages.

The products described on this website may not be offered for sale in all countries and are, in every instance, reserved for those investors who are entitled to buy the products. The information and content in these web pages is therefore not intended for natural persons or legal entities whose domicile or company headquarters is subject to a legal system that provides for restrictions in the dissemination of such information. Natural persons or legal entities whose domicile or company headquarters is subject to a foreign legal system should find out about the aforementioned restrictions and observe them appropriately.

In particular, the information contained on this website is not intended for the US. US citizens, as defined by Regulation S of the 1933 US Securities Act, and legal entities resident in the US are prohibited from accessing these web pages. In addition the information provided on these web pages may not be disseminated or passed on in the US. The products listed here are not and will not be registered in accordance with the 1933 US Securities Act and no approval in accordance with the 1936 US Commodities Exchange Act has been obtained for trading with these products. The products may not be sold or offered in the US, to US citizens or to legal entities resident in the US.